PRESS-RELEASE ·Filed Sep 18, 2026
Press release · Activist
Actionable Insight • Neutral
Routine new-hire equity grant — no immediate stock-moving catalyst. Monitor upcoming pipeline catalysts (e.g., acoramidis regulatory decisions) for material events.
Latest settled — T+20d
BBIO ▲ +2.04% at T+20d
NEUTRAL call +2.04% · α vs SPY +2.95% · entry $66.58 → $67.94
Latest observation: T+26 +5.63% FF3 residual α
T+1d
+3.98%
call +3.98% · α +4.00%
$69.23
settled 5w ago
T+5d
+0.05%
call +0.05% · α +1.07%
$66.61
settled 5w ago
T+20d
+2.04%
call +2.04% · α +2.95%
$67.94
settled 12d ago
T+60d
Pending
in 7w
Price Chart
Loading chart...
Executive Summary
BridgeBio Pharma granted 63,009 restricted stock units to 36 new employees as an inducement material to their employment, with a one-year cliff vesting schedule starting November 2027. This is a routine equity grant for new hires, not a material financial event.
Key Facts
- Equity grants of 63,009 RSUs approved to 36 new employees on September 18, 2026
- One-fourth of shares vest on November 16, 2027, with quarterly vesting thereafter
- Grants made under Nasdaq Listing Rule 5635(c)(4) as inducement material to employment
- Plan originally adopted November 2019, amended and restated in February and December 2023
Financial Impact
63,009 shares granted; no dollar value stated
dilution
Risk Factors
- No financial or operational data provided in this filing
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3364934 |
33 reports for BBIO
70% Hit rate @ T+20 Went positive at some point 11 of 13 best @ T+60▲ +26.76%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $68.25 | awaiting T+20 | — | $69.37 (+1.64%) |
Oct 22, 2026 5d ago | Press Release | $68.12 | awaiting T+20 | — | $69.37 (+1.84%) |
Oct 13, 2026 14d ago | 8-K | $63.30 | awaiting T+20 | — | $69.37 (+9.59%) |
Oct 6, 2026 21d ago | Press Release | $66.96 | awaiting T+20 | — | $69.37 (+3.60%) |
Oct 5, 2026 22d ago | Press Release | $66.96 | awaiting T+20 | — | $69.37 (+3.60%) |
Oct 5, 2026 22d ago | Press Release | $66.14 | awaiting T+20 | — | $69.37 (+4.88%) |
Sep 18, 2026 5w ago | Press Release | $66.58 $67.94 | ▲ +2.04% | ▲ +2.95% | $69.37 (+4.19%) |
Aug 31, 2026 8w ago | 8-K | $76.59 $65.97 | ▼ −13.87% | ▼ −13.68% | $69.37 (−9.43%) |
Aug 26, 2026 8w ago | Press Release | $79.37 $66.28 | ▼ −16.49% | ▼ −16.72% | $69.37 (−12.60%) |
Aug 22, 2026 9w ago | Institutional Cluster | $81.07 $69.23 | ▼ −14.60% | ▼ −15.92% | $69.37 (−14.43%) |
Showing 10 of 33
US Market Status
Market Closed — Opens in 6h 36m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers